Multidisciplinary management for primary uterine osteosarcoma, including gene panel testing: case report and literature review.

IF 0.5 Q4 ONCOLOGY

International Cancer Conference Journal Pub Date : 2023-05-09 eCollection Date: 2023-10-01 DOI:10.1007/s13691-023-00613-x

Takako Kusanishi, Naotake Tanaka, Mizue Itoi, Miwa Ijiri, Keiko Ebisawa, Kiyomi Suzuka, Youko Hagiwara, Tukasa Yonemoto, Akinobu Araki, Makiko Itami

{"title":"Multidisciplinary management for primary uterine osteosarcoma, including gene panel testing: case report and literature review.","authors":"Takako Kusanishi, Naotake Tanaka, Mizue Itoi, Miwa Ijiri, Keiko Ebisawa, Kiyomi Suzuka, Youko Hagiwara, Tukasa Yonemoto, Akinobu Araki, Makiko Itami","doi":"10.1007/s13691-023-00613-x","DOIUrl":null,"url":null,"abstract":"<p><p>Primary osteosarcoma of the uterus (uOS) is rare, and its standard treatment has not yet been established. Herein, we present the case of a 50-year-old woman with uOS who demonstrated an improved prognosis after multiple surgeries to the metastatic sites. After the initial diagnosis of uOS, the patient showed recurrence and distant metastasis and hence expected to exhibit a poor prognosis. The patient underwent multiple surgical resections of the metastatic as well as primary tumors, which enabled the patient to survive for 24 months after the initial surgery. Considering that the median survival time of patients with uOS is approximately 6 months, the survival rate of our patient is noteworthy. Based on our observations, it is suggested that the resection of the primary and metastatic tumors might contribute to the extension of the survival period of the patient with chemo-resistant uOS.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"12 4","pages":"241-247"},"PeriodicalIF":0.5000,"publicationDate":"2023-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10421837/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Cancer Conference Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13691-023-00613-x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Primary osteosarcoma of the uterus (uOS) is rare, and its standard treatment has not yet been established. Herein, we present the case of a 50-year-old woman with uOS who demonstrated an improved prognosis after multiple surgeries to the metastatic sites. After the initial diagnosis of uOS, the patient showed recurrence and distant metastasis and hence expected to exhibit a poor prognosis. The patient underwent multiple surgical resections of the metastatic as well as primary tumors, which enabled the patient to survive for 24 months after the initial surgery. Considering that the median survival time of patients with uOS is approximately 6 months, the survival rate of our patient is noteworthy. Based on our observations, it is suggested that the resection of the primary and metastatic tumors might contribute to the extension of the survival period of the patient with chemo-resistant uOS.

查看原文本刊更多论文

原发性子宫骨肉瘤的多学科治疗，包括基因组检测：病例报告和文献综述。

原发性子宫骨肉瘤（uOS）是罕见的，其标准治疗方法尚未确定。在此，我们介绍了一例50岁的uOS妇女，她在对转移部位进行多次手术后，预后有所改善。在最初诊断为uOS后，患者出现复发和远处转移，因此预计预后不佳。患者接受了多次转移性和原发性肿瘤的手术切除，这使患者能够在初次手术后存活24个月。考虑到uOS患者的中位生存时间约为6个月，我们患者的生存率值得注意。根据我们的观察，原发性和转移性肿瘤的切除可能有助于延长化疗耐药uOS患者的生存期。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Cancer Conference Journal ONCOLOGY-

自引率

14.30%

发文量

期刊介绍： This online-only journal publishes original case reports on all types of cancer. In particular, we welcome not only case reports of educational value in the diagnosis and treatment of cancers, but also reports on molecularly analyzed cancer cases, including gene mutations, gene fusions, gene expression, and changes in copy number, regardless of their known clinical significance. Assessing the molecular analysis of a tumor usually requires a “cancer conference” in which experts from various fields discuss it. Even if the authors and their respective “cancer conference” were unable to determine the clinical significance of molecular changes at the time of submission and publication, their data may provide evidence that will help the scientific community develop precision medicine solutions in the future. We welcome case reports with reviews of the literature on similar cases, as they are more useful and valuable to readers than are reports of rare cases. International Cancer Conference Journal is the official publication of the Japan Society of Clinical Oncology (JSCO). - Presents an online-only collection of original case reports on all types of cancer - In particular, welcomes molecularly analyzed cancer cases - The Official Publication of the Japan Society of Clinical Oncology (JSCO)